Bisphosphonates Use After Total Joint Arthroplasty

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

27405 participants

Study Classification

OBSERVATIONAL

Study Start Date

2000-01-01

Study Completion Date

2022-11-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background Bisphosphonates has been associated with a decreased risk of revision total joint replacements because of its effects on decreased periprosthetic bone loss and prosthetic migration. However, the results in the early literature are inconsistent and the influence of bisphosphonates on associated complications and subsequent total joint arthroplasty (TJA) remains unknown. This study is to investigate the association between the use of bisphosphonates and risk of adverse outcomes after primary TJA.

Materials and Methods This matched cohort study utilized National Health Insurance Research Database in Taiwan to identify patients who underwent primary TJA over a 15-year period (January 2000- December 2015 inclusive). Study participants were further categorized into two groups: bisphosphonates users and nonusers, using propensity score matching. The Kaplan-Meier curve analysis and adjusted hazard ratios (aHR) of revision surgery, adverse outcomes of primary surgery and undergoing subsequent TJA were calculated using Cox regression analysis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty

NCT00772395

Bone Loss

COMPLETED PHASE4

The Effect of Long-term Use of Bisphosphonates on Femur Morphology

NCT06621069

Osteoporosis Knee Osteoarthristis

COMPLETED

The Effectiveness of Two Osteoporosis Drugs on Prosthetic Bone Mineral Density (BMD) Loss After Total Hip Arthroplasty(THA)

NCT01020253

Bone Density Arthroplasty, Replacement, Hip

UNKNOWN NA

Abaloparatide Before Total Knee Arthroplasty

NCT04167163

Osteoporosis Arthroplasties, Knee Replacement

COMPLETED PHASE4

Anabolic Therapy in Postmenopausal Osteoporosis

NCT05010590

Postmenopausal Osteoporosis

ACTIVE_NOT_RECRUITING PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diphosphonates

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

bisphosphonates users

Patients who underwent primary total joint arthroplasty with bisphosphonates use

Bisphosphonates, Combinations

Intervention Type DRUG

bisphosphonates nonusers

Patients who underwent primary total joint arthroplasty without bisphosphonates use

Bisphosphonates, Combinations

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bisphosphonates, Combinations

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients who underwent primary total joint arthroplasty during the study period (January 1, 2000 to December 31, 2015).

Exclusion Criteria

1. Patients with total joint arthroplasty before the index date,
2. Patients with existing pathologic fracture, nonunion of fracture and partial joint replacement,
3. Patients who were lost to follow-up
4. Patients \< 40 years old

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No